Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Administration

2 evidence topics · 2 sources

Route and schedule
FieldQuoted record
Experimental arm“CTX-009 plus Paclitaxel”
CTX-009 administration“IV infusion on day 1 and 14 of every 28 day cycle”
Paclitaxel administration“IV infusion on day 1, 8, and 15 of every 28 day cycle”
Infusion preparation and duration in the phase 1 study

“Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h. ABL001/CTX‐009 was administered in a 2‐week cycle, with the exception of the second dose, which had a 3‐week interval. Administration continued until unacceptable toxicity or disease progression was identified according to RECIST version 1.1.” (opens the source at this quote in a new tab)

Premedication, infusion-rate modification, and preparation instructions for the commercial product

No evidence found.